UPDATE 1-Warner Chilcott Q4 profit beats market expectations

(Recasts; adds details)

Feb 29 (Reuters) - Prescription drugmaker Warner Chilcott Ltd (WCRX.O) reported better-than-expected quarterly results driven by the rise in revenue of oral contraceptives and dermatology products. Warner Chilcott reported fourth-quarter net income of $19.7 million, or 8 cents a share, compared with a net loss of $8.5 million, or 3 cents a share in the prior year quarter. Adjusted cash net income was 30 cents a share.

Revenue rose 10.3 percent to $227.7 million.

Analysts were expecting earnings of 26 cents a share, before special items, on revenue of $220.4 million, according to Reuters Estimates.

Sales of oral contraceptive products increased 13.9 percent, helped by a 93.8 percent rise in filled prescriptions for Loestrin 24 FE.

Sales of dermatology products rose 14.3 percent. (Reporting by Esha Dey in Bangalore; Editing by Bernard Orr)